Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

GlaxoSmithKline’s Lamictal Obtains MHLW Approval

This article was originally published in PharmAsia News

Executive Summary

GlaxoSmithKline announced Oct. 16 it obtained a new drug approval for epilepsy drug Lamictal (lamotrigine)from Japan's Ministry of Health, Labor and Welfare. The drug is the first epilepsy drug in Japan that is indicated to treat patients from children to seniors and patients with intractable epilepsy. GSK plans to launch the drug in early December. (Click here for more - Japanese language

Table

View full table

Tags:
Latest Headlines

Japan Results Roundup: Weak Yen Provides A Boost But Some Sales Challenges Emerge

Deal Watch: Bristol Adds To Vaccines ‘Repertoire,’ Takes ‘Scenic’ View Of Cellular Pathways

Navigating A Transition Year: Five Takeaways From Pfizer’s Q1 Call

Astellas Stakes Claim In CAR-Ts For Solid Tumors With Poseida Deal

See All
UsernamePublicRestriction

Register

SC066931

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By